VALENSIN, PIER EGISTO
 Distribuzione geografica
Continente #
NA - Nord America 4.957
EU - Europa 3.335
AS - Asia 2.080
SA - Sud America 327
AF - Africa 119
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.825
Nazione #
US - Stati Uniti d'America 4.921
CN - Cina 825
RU - Federazione Russa 713
GB - Regno Unito 637
SG - Singapore 589
IE - Irlanda 530
UA - Ucraina 345
SE - Svezia 302
BR - Brasile 275
DE - Germania 248
FR - Francia 244
VN - Vietnam 193
HK - Hong Kong 173
FI - Finlandia 127
KR - Corea 115
IT - Italia 76
ZA - Sudafrica 65
IN - India 49
ES - Italia 32
BD - Bangladesh 21
NG - Nigeria 20
JP - Giappone 17
MX - Messico 16
PL - Polonia 15
AR - Argentina 14
IQ - Iraq 14
CA - Canada 13
NL - Olanda 12
UZ - Uzbekistan 11
BE - Belgio 10
CZ - Repubblica Ceca 10
EC - Ecuador 10
TR - Turchia 10
ID - Indonesia 8
MA - Marocco 8
CO - Colombia 6
JO - Giordania 6
SA - Arabia Saudita 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
CI - Costa d'Avorio 5
KG - Kirghizistan 5
LB - Libano 5
LT - Lituania 5
PK - Pakistan 5
CL - Cile 4
HU - Ungheria 4
LU - Lussemburgo 4
PE - Perù 4
PH - Filippine 4
RS - Serbia 4
BO - Bolivia 3
DZ - Algeria 3
IR - Iran 3
MW - Malawi 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
UY - Uruguay 3
AT - Austria 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ET - Etiopia 2
GR - Grecia 2
HR - Croazia 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
PY - Paraguay 2
SC - Seychelles 2
TN - Tunisia 2
AF - Afghanistan, Repubblica islamica di 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
DK - Danimarca 1
EU - Europa 1
GE - Georgia 1
IL - Israele 1
IM - Isola di Man 1
JM - Giamaica 1
KE - Kenya 1
MD - Moldavia 1
ML - Mali 1
MN - Mongolia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
SD - Sudan 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 10.825
Città #
Dallas 573
Southend 539
Dublin 524
Fairfield 520
Ashburn 391
Singapore 326
Chandler 317
Jacksonville 271
Woodbridge 249
Menlo Park 236
Santa Clara 235
Moscow 203
Houston 183
Wilmington 179
Cambridge 178
Seattle 178
Beijing 174
Hong Kong 162
Ann Arbor 155
Hefei 114
Seoul 114
San Jose 101
Princeton 93
Nanjing 92
The Dalles 83
New York 78
Ho Chi Minh City 67
Johannesburg 61
Los Angeles 59
Munich 56
Helsinki 55
Hanoi 53
Lauterbourg 48
Shanghai 41
Boardman 40
Nanchang 33
San Diego 30
Buffalo 24
London 21
San Mateo 21
São Paulo 21
Abuja 19
Columbus 19
Frankfurt am Main 18
Málaga 18
Turku 18
Venezia 18
Hebei 17
Siena 17
Council Bluffs 16
Lancaster 16
Redondo Beach 16
Jiaxing 15
Tianjin 15
Changsha 14
Orem 14
Shenyang 14
Tokyo 11
Warsaw 11
Washington 11
Brooklyn 10
Chennai 10
Dearborn 10
Haiphong 10
Kunming 10
Bengaluru 9
Brussels 9
Norwalk 9
San Francisco 9
Chicago 8
Da Nang 8
Denver 8
Guangzhou 8
Redwood City 8
Tashkent 8
Jinan 7
Renton 7
Zhengzhou 7
Amman 6
Belo Horizonte 6
Boston 6
Brno 6
Düsseldorf 6
Guarulhos 6
Hangzhou 6
Phoenix 6
Porto Alegre 6
Rio de Janeiro 6
Toronto 6
Abidjan 5
Bishkek 5
Changchun 5
Fremont 5
Lanzhou 5
Madrid 5
Mumbai 5
Ankara 4
Brasília 4
Curitiba 4
Dubai 4
Totale 7.467
Nome #
Antipeptide monoclonal antibodies inhibit the binding of rabiesvirus glycoprotein and alpha-bungarotoxin to the nicotinic acetylcholine receptor 359
Antigenicity and immunogenicity of the V3 domain of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. AIDS Res Hum Retroviruses 311
Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type 1 nucleoside reverse transcriptase inhibitors 269
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples 263
Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. 252
Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine and protease inhibitors 249
Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. 247
Structure of rubella E1 glycoprotein epitopes established by multiple peptide synthesis 244
Helicobacter pylori infection and infertility 231
Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. 231
Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8 coinfected patients 231
Characterization of immunoreactive octapeptides of human-cytomegalovirus gp58 227
Biotechnology for virus vaccine design, production, and control 225
Proprietà di legame di anticorpi monoclonali contro il virus della rabbia ottenuti per mezzo di immunizzazione con un peptide sintetico 224
Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. 223
Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. 221
Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy 218
Fast duplex one-step RT-PCR for rapid differential diagnosis of entero- or toscana virus meningitis 217
Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. 216
Hepatitis C virus infection and myositis: a polymerase chain reaction study 215
Microfilament and microtubule alterations in cultured CHO cells during methyl mercury intoxication and protection with selenite 214
The potential role of hepatitis C virus in the pathogenesis of the neurological syndrome in chronic hepatitis C 212
Synthetic peptides of rubella E1 glycoprotein for serological assays 197
Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy 197
Evaluation of cell-free and cell-associated peripheral blood HIV-1 RNA response to antiretroviral therapy 194
Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 plasma RNA. 192
Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment 189
Nested polymerase chain reaction for detection of human immunodeficiency virus type 1 DNA in clinical specimens. 183
Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype 183
Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein 176
Optimal conditions for detection of human immunodeficiency virus type 1 DNA by polymerase chain reaction with nested primers 176
Rapid identification of Toscana virus by nested PCR during an outbreak in the Siena area of Italy 174
Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice 173
Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from human immunodeficiency virus type 1 genotype 173
NMR investigation of cell cultures: early detection of infection by Herpes simplex virus type 2 and transformation 172
Binding properties of monoclonal antibodies to rabies virus 170
Live-cell immunofluorescence for detection of human immunodeficiency virus type 1 (HIV-1)-related antigens in peripheral blood mononuclear cells from HIV-1-seropositive individuals 169
Low human immunodeficiency virus titer and polymerase chain reaction false-negatives 169
Human immunodeficiency virus-1 infection, homosexuality, and Kaposi-associated herpes-like DNA in peripheral blood mononuclear cells 169
Comparison of M-MLV reverse transcriptase and Tth polymerase activity in RT-PCR of samples with low virus burden 165
Identification of Mycobacterium tuberculosis complex, Mycobacterium avium and Mycobacterium intracellulare by selective nested polymerase chain reaction 164
Increased reliability of 'selective PCR' using additionally mutated primers and a commercial 'Taq DNA polymerase enhancer' 161
Specific antibody patterns over a two-year period after rubella immunization with RA 27/3 live attenuated vaccine 156
Evaluation of the specific immune response after anti-rubella vaccination [Valutazione della risposta immunitaria specifica dopo vaccinazione anti-rosolia] 151
Lack of efficacy of ozone therapy in HIV infection 150
Expression of measles virus antigens in Streptococcus gordonii 149
Expression of recombinant E2 and C proteins of rubella virus in insect cells 145
Rapid detection and typing of circulating mumps virus by reverse transcription/polymerase chain reaction 142
Streptococcus gordonii as a live vaccine vector [Lo Streptococcus gordonii come vettore di vaccini ricombinanti] 141
Ultrasensitive in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma 140
Low human immunodeficiency virus type 1 (HIV-1)DNA burden as a major cause for failure to detect HIV-1 DNA in clinical specimens by PCR 139
Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis 138
Serological evidence of reinfection among vaccinees during rubella outbreak 137
Simultaneous amplification of multiple human immunodeficiency virus type 1 DNA sequences from clinical specimens by using nested-primer polymerase chain reaction 131
Viral childhood gastroenteritis 129
Rubella epidemiology over a 14-year period in Siena (Italy): a retrospective serological survey 120
Polymerase chain reaction for detection of human immunodeficiency virus type 1 DNA in peripheral lymphocytes. Results in subjects with high risk of HIV infection 40
Totale 10.853
Categoria #
all - tutte 31.966
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.966


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021142 0 0 0 0 0 0 0 0 0 39 68 35
2021/2022595 37 79 23 51 51 9 36 20 30 80 44 135
2022/20231.093 66 97 149 163 102 229 8 98 90 27 37 27
2023/2024799 23 19 95 48 27 268 263 15 3 4 1 33
2024/20251.429 35 75 126 58 197 86 22 75 128 46 153 428
2025/20263.202 287 469 517 350 660 121 386 143 106 163 0 0
Totale 10.853